欧洲12登记库24195例初治axSpA患者启动TNFi的应答与药物留存率
12个月留存率为80%(95%CI 79%~80%),各登记库间范围为71%~94%;6个月ASDAS inactive disease/BASDAI<40率为33%/72%(LUNDEX校正后27%/59%),ASAS 20/40应答率为64%/49%(LUNDEX校正后52%/40%)。
要点
- 12个月TNFi留存率80%,各登记库间异质性明显(71%~94%)。
- 6个月LUNDEX校正后ASDAS inactive disease率27%,BASDAI<40率59%。
- nr-axSpA患者12个月留存率73%,6个月LUNDEX校正应答率更低。
核心结论
- 在常规诊疗中首次启动TNFi的axSpA患者中,6个月27%达到ASDAS inactive disease、59%达到BASDAI<40,五分之四患者1年后仍在继续治疗。
主要发现
- 各登记库间基线特征存在异质性。
- 12个月留存率为80%(95%CI 79%~80%),各登记库间范围为71%~94%。
- 6个月ASDAS inactive disease/BASDAI<40率为33%/72%(LUNDEX校正后27%/59%),ASAS 20/40应答率为64%/49%(LUNDEX校正后52%/40%)。
- 2009年后启动首次TNFi的患者中,6097例登记符合ASAS axSpA标准,2935例符合改良纽约强直性脊柱炎标准,1178例登记为nr-axSpA。
- nr-axSpA患者12个月留存率较低,为73%(70%~76%),6个月LUNDEX校正应答率也较低(ASDAS inactive disease/BASDAI40为20%/50%,ASAS 20/40为45%/33%)。
关键数值与推荐
- ASDAS inactive disease定义为<1.3,BASDAI<40 mm,ASAS 20/40应答按相应标准评估。
临床怎么用
- 常规诊疗中初治axSpA患者启动TNFi后约五分之四可维持治疗至1年,6个月约四分之一至三分之一达到ASDAS inactive disease。
- nr-axSpA患者TNFi留存率与6个月应答率均低于整体人群,临床决策时需考虑此差异。
局限性
- 各登记库基线特征存在异质性,可能影响留存率与应答率的可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). METHODS: Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months. RESULTS: A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%-76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009-2014. CONCLUSION: A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.
引用
- Ørnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019. PMID: 31431486. doi:10.1136/annrheumdis-2019-215427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。